CMS Approves Coverage for T-TEER to Treat Tricuspid Regurgitation

July 11, 2025—The United States Centers for Medicare & Medicaid Services (CMS) recently announced it has issued a National Coverage Determination (NCD) that covers FDA-approved tricuspid transcatheter edge-to-edge repair (T-TEER) for the treatment of symptomatic tricuspid regurgitation (TR) under Coverage with Evidence Development (CED), when furnished in accordance with the coverage criteria specified in the NCD.

The complete NCD decision memorandum is available on the CMS website here.

The decision memorandum states that T-TEER is covered when furnished according to an FDA market-authorized indication and all the criteria outlined therein are met, including that the T-TEER items and services are furnished in the context of a CMS-approved CED study.

CMS advised that the TRICARE study meets the requirements for coverage under the CED. TRICARE is sponsored by Abbott, manufacturer of the TriClip G5 system.

In April 2024, Abbott announced FDA approval of the TriClip TEER system for the treatment of TR. The company announced CE Mark approval of TriClip in 2020.

In comments to Cardiac Interventions Today, Sandra Lesenfants, Senior Vice President of Abbott’s Structural Heart business, stated, “This CMS decision offers new hope to patients with symptomatic TR by expanding access to the minimally invasive technology of Abbott’s TriClip G5 system. We’re proud to deliver a treatment option that can significantly improve quality of life for those with limited alternatives and help people get back to living life on their terms.”